Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/30/2025 | $41.00 | Buy | Guggenheim |
| 4/2/2025 | $14.00 | Sector Outperform → Sector Perform | Scotiabank |
| 3/7/2025 | $50.00 | Sector Outperform | Scotiabank |
| 1/22/2025 | $30.00 | Hold | Stifel |
| 11/22/2024 | $45.00 | Outperform | Evercore ISI |
| 3/7/2024 | $48.00 | Overweight | Piper Sandler |
| 5/1/2023 | Buy | Truist | |
| 8/25/2022 | $5.00 | Neutral → Sell | Goldman |
– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – – On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne) in the second quarter of 2025 – – Expect to report data from Part D of the Phase 2 CIRRUS-HCM trial in the second half of 2025 – BOULDER, Colo., May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today reported financial results
BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025, subject to the satisfaction of customary closing conditions. The deal
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function – – EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from th
10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)
8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
DEFA14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)
SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)
– Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos
– EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month
- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin
– President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox brings considerable expertise in clinical development and regulatory strategy to Edgewise, serving currently as President and CMO at BridgeBio Pharma, and previously as CMO at MyoKardia, where he was one of the inventors of Camzyos
– Former Chief Medical Officer of MyoKardia and Renovacor to lead cardiovascular development at Edgewise – Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer (CMO) at Renovacor through its acquisition by Rocket Pharmaceuticals, Inc., and previously served as CMO and Senior Vice President o
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
Guggenheim initiated coverage of Edgewise Therapeutics with a rating of Buy and set a new price target of $41.00
Scotiabank downgraded Edgewise Therapeutics from Sector Outperform to Sector Perform and set a new price target of $14.00
Scotiabank initiated coverage of Edgewise Therapeutics with a rating of Sector Outperform and set a new price target of $50.00
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)